489 related articles for article (PubMed ID: 28193767)
21. Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
Shrestha A; Kim N; Lee SJ; Jeon YH; Song JJ; An H; Cho SJ; Kadayat TM; Chin J
J Med Chem; 2021 Oct; 64(20):14913-14929. PubMed ID: 34488340
[TBL] [Abstract][Full Text] [Related]
22. The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate.
Li Y; Trojer P; Xu CF; Cheung P; Kuo A; Drury WJ; Qiao Q; Neubert TA; Xu RM; Gozani O; Reinberg D
J Biol Chem; 2009 Dec; 284(49):34283-95. PubMed ID: 19808676
[TBL] [Abstract][Full Text] [Related]
23. Histone lysine methyltransferases in biology and disease.
Husmann D; Gozani O
Nat Struct Mol Biol; 2019 Oct; 26(10):880-889. PubMed ID: 31582846
[TBL] [Abstract][Full Text] [Related]
24. Multiple-myeloma-related WHSC1/MMSET isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity.
Kim JY; Kee HJ; Choe NW; Kim SM; Eom GH; Baek HJ; Kook H; Kook H; Seo SB
Mol Cell Biol; 2008 Mar; 28(6):2023-34. PubMed ID: 18172012
[TBL] [Abstract][Full Text] [Related]
25. Understanding the language of Lys36 methylation at histone H3.
Wagner EJ; Carpenter PB
Nat Rev Mol Cell Biol; 2012 Jan; 13(2):115-26. PubMed ID: 22266761
[TBL] [Abstract][Full Text] [Related]
26. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
[TBL] [Abstract][Full Text] [Related]
27. Depletion of H3K36me2 recapitulates epigenomic and phenotypic changes induced by the H3.3K36M oncohistone mutation.
Rajagopalan KN; Chen X; Weinberg DN; Chen H; Majewski J; Allis CD; Lu C
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619101
[TBL] [Abstract][Full Text] [Related]
28. Mixed lineage leukemia: histone H3 lysine 4 methyltransferases from yeast to human.
Malik S; Bhaumik SR
FEBS J; 2010 Apr; 277(8):1805-21. PubMed ID: 20236312
[TBL] [Abstract][Full Text] [Related]
29. Role of somatic cancer mutations in human protein lysine methyltransferases.
Kudithipudi S; Jeltsch A
Biochim Biophys Acta; 2014 Dec; 1846(2):366-79. PubMed ID: 25123655
[TBL] [Abstract][Full Text] [Related]
30. The T1150A cancer mutant of the protein lysine dimethyltransferase NSD2 can introduce H3K36 trimethylation.
Khella MS; Schnee P; Weirich S; Bui T; Bröhm A; Bashtrykov P; Pleiss J; Jeltsch A
J Biol Chem; 2023 Jun; 299(6):104796. PubMed ID: 37150325
[TBL] [Abstract][Full Text] [Related]
31. Understanding the Roles of the NSD Protein Methyltransferases in Head and Neck Squamous Cell Carcinoma.
Murali M; Saloura V
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360250
[TBL] [Abstract][Full Text] [Related]
32. Structure, Activity and Function of the NSD3 Protein Lysine Methyltransferase.
Rathert P
Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440470
[TBL] [Abstract][Full Text] [Related]
33. The H3.3 G34W oncohistone mutation increases K36 methylation by the protein lysine methyltransferase NSD1.
Bröhm A; Schoch T; Grünberger D; Khella MS; Schuhmacher MK; Weirich S; Jeltsch A
Biochimie; 2022 Jul; 198():86-91. PubMed ID: 35341929
[TBL] [Abstract][Full Text] [Related]
34. Functional characterization of the zebrafish WHSC1-related gene, a homolog of human NSD2.
Yamada-Okabe T; Imamura K; Kawaguchi N; Sakai H; Yamashita M; Matsumoto N
Biochem Biophys Res Commun; 2010 Nov; 402(2):335-9. PubMed ID: 20946879
[TBL] [Abstract][Full Text] [Related]
35. The role of SET domain containing lysine methyltransferase 7 in tumorigenesis and development.
Yang S; Wang X; Bai J; Duan B
Cell Cycle; 2023 Feb; 22(3):269-275. PubMed ID: 36101480
[TBL] [Abstract][Full Text] [Related]
36. Writing, erasing and reading histone lysine methylations.
Hyun K; Jeon J; Park K; Kim J
Exp Mol Med; 2017 Apr; 49(4):e324. PubMed ID: 28450737
[TBL] [Abstract][Full Text] [Related]
37. ING2 recruits histone methyltransferase activity with methylation site specificity distinct from histone H3 lysines 4 and 9.
Goeman F; Otto K; Kyrylenko S; Schmidt O; Baniahmad A
Biochim Biophys Acta; 2008 Oct; 1783(10):1673-80. PubMed ID: 18513492
[TBL] [Abstract][Full Text] [Related]
38. Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention.
Shen C; Vakoc CR
Curr Opin Oncol; 2015 Jan; 27(1):57-63. PubMed ID: 25402979
[TBL] [Abstract][Full Text] [Related]
39. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract][Full Text] [Related]
40. Histone H3K4 methylation-dependent and -independent functions of Set1A/COMPASS in embryonic stem cell self-renewal and differentiation.
Sze CC; Cao K; Collings CK; Marshall SA; Rendleman EJ; Ozark PA; Chen FX; Morgan MA; Wang L; Shilatifard A
Genes Dev; 2017 Sep; 31(17):1732-1737. PubMed ID: 28939616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
